The Insulin-Like Growth Factor System in Cancer
- 7 June 2012
- journal article
- research article
- Published by Elsevier BV in Endocrinology and Metabolism Clinics of North America
- Vol. 41 (2), 335-350
- https://doi.org/10.1016/j.ecl.2012.04.014
Abstract
No abstract availableKeywords
This publication has 129 references indexed in Scilit:
- Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studiesThe Lancet Oncology, 2010
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyThe Lancet Oncology, 2009
- Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and CarboplatinJournal of Thoracic Oncology, 2009
- Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastomaNeuro-Oncology, 2009
- A complex interplay between Akt, TSC2 and the two mTOR complexesBiochemical Society Transactions, 2009
- Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumorsProceedings of the National Academy of Sciences of the United States of America, 2008
- Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activationBiochemical Journal, 2007
- Treatment goals in ovarian cancerInternational Journal of Gynecologic Cancer, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysisThe Lancet, 2004